JPT Peptide Technologies and Cancer Immunotherapy Trials Network Collaborate on Monitoring Cellular Immune Responses

Berlin, Germany, April 16th, 2013 – JPT Peptide Technologies GmbH, a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), and the Cancer Immunotherapy Trials Network (CITN, Seattle, WA, USA) today agreed on the use of JPT’s PepMix™ Peptide Pool Platform to support CITN’s clinical cancer trials and cancer research related efforts. 
Within the scope of the collaboration JPT will assemble and provide a large panel of high-grade antigen spanning PepMix™ Peptide Pools related to a variety of tumor associated antigens targeted in CITN’s immunotherapy trials.
“For several years now, vaccine development and immunotherapy endeavours in industrial and non-profit environments have taken advantage of our proprietary approach to designing and chemically synthesizing antigen spanning peptide pools under regulated conditions” states Holger Wenschuh, CEO at JPT. He adds “Following several published successes utilizing our peptide pools, we are delighted to partner with CITN  to further exploit these reagents as unique immune monitoring tools.”

About JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH
is an DIN ISO 9001:2008 certified research and development partner and innovative service provider for peptide related projects.  JPT’s key technologies SPOT™– for ultra-high-throughput peptide synthesis and screening, PepStar™ – for high-content peptide microarrays, PepTrack™  - for flexible peptide library assembly, PepMix™PepMix™ Peptide Pools – for antigen specific T-cell stimulation using peptide pools, and SpikeTide™ – for protein biomarker quantification accelerate research and development in areas such as immune monitoring, vaccine development, peptide biomarker discovery, peptide lead identification and optimization, enzyme profiling and proteomics.

For further information please contact:
JPT Peptide Technologies GmbH
Dr. Holger Wenschuh
Volmerstr. 5
12555 Berlin/Germany
Tel: +49 -30 -6392 5500
Fax: +49-30-6392 5501

Stay in touch and be the first to receive the latest news!